Compare Stocks: AARD, RLMD, AVIR, and FENC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$5.38 -6.1%	$6.33	$3.35 ▼ $17.94	$117.74M	3.74	123,002 shs	257,808 shs
AVIR Atea Pharmaceuticals	$5.83 +0.2%	$5.03	$2.78 ▼ $6.45	$467.60M	0.28	230,468 shs	199,139 shs
FENC Adherex Technologies	$12.39 -1.3%	$11.01	$5.65 ▼ $13.25	$434.37M	1.1	284,493 shs	212,437 shs
RLMD Relmada Therapeutics	$4.43 +1.4%	$5.29	$1.30 ▼ $8.00	$472.55M	0.45	1.08 million shs	675,553 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	-6.11%	-7.08%	-28.46%	+46.20%	-34.23%
AVIR Atea Pharmaceuticals	+0.17%	+8.77%	+22.74%	+37.18%	+68.50%
FENC Adherex Technologies	-1.27%	+0.98%	+17.78%	+42.41%	+39.84%
RLMD Relmada Therapeutics	+1.37%	+2.31%	-18.57%	-25.55%	+201.36%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$5.38 -6.1%	$6.33	$3.35 ▼ $17.94	$117.74M	3.74	123,002 shs	257,808 shs
AVIR Atea Pharmaceuticals	$5.83 +0.2%	$5.03	$2.78 ▼ $6.45	$467.60M	0.28	230,468 shs	199,139 shs
FENC Adherex Technologies	$12.39 -1.3%	$11.01	$5.65 ▼ $13.25	$434.37M	1.1	284,493 shs	212,437 shs
RLMD Relmada Therapeutics	$4.43 +1.4%	$5.29	$1.30 ▼ $8.00	$472.55M	0.45	1.08 million shs	675,553 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	-6.11%	-7.08%	-28.46%	+46.20%	-34.23%
AVIR Atea Pharmaceuticals	+0.17%	+8.77%	+22.74%	+37.18%	+68.50%
FENC Adherex Technologies	-1.27%	+0.98%	+17.78%	+42.41%	+39.84%
RLMD Relmada Therapeutics	+1.37%	+2.31%	-18.57%	-25.55%	+201.36%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	2.42	Hold	$15.33	185.01% Upside
AVIR Atea Pharmaceuticals	2.33	Hold	$7.00	20.07% Upside
FENC Adherex Technologies	2.50	Moderate Buy	$17.00	37.21% Upside
RLMD Relmada Therapeutics	2.75	Moderate Buy	$12.00	170.88% Upside

Current Analyst Ratings Breakdown

Latest AARD, RLMD, AVIR, and FENC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	AVIR Atea Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$6.00 ➝ $7.00
8/12/2026	FENC Adherex Technologies	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$16.00 ➝ $18.00
8/12/2026	FENC Adherex Technologies	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$13.00 ➝ $16.00
7/20/2026	AARD Aardvark Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$6.00
7/17/2026	AVIR Atea Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	FENC Adherex Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/2/2026	AARD Aardvark Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/18/2026	RLMD Relmada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
6/18/2026	RLMD Relmada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/18/2026	RLMD Relmada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	$3.42 per share	N/A
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$2.55 per share	N/A
FENC Adherex Technologies	$44.64M	9.73	N/A	N/A	$1.21 per share	10.24
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$1.94 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	-$57.59M	-$3.21	N/A	N/A	N/A	N/A	-71.54%	-64.94%	N/A
AVIR Atea Pharmaceuticals	-$158.35M	-$2.08	N/A	N/A	N/A	N/A	-64.25%	-57.12%	11/11/2026 (Estimated)
FENC Adherex Technologies	-$9.74M	-$0.13	N/A	12.64	N/A	-6.09%	-5.71%	-2.37%	11/12/2026 (Estimated)
RLMD Relmada Therapeutics	-$57.38M	-$0.90	N/A	N/A	N/A	N/A	-47.52%	-43.97%	11/12/2026 (Estimated)

Latest AARD, RLMD, AVIR, and FENC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	FENC Adherex Technologies	$0.02	$0.05	+$0.03	$0.05	$16.21 million	$17.87 million
8/12/2026	Q2 2026	AVIR Atea Pharmaceuticals	-$0.5550	-$0.41	+$0.1450	-$0.41	$33.03 million	N/A
8/11/2026	Q2 2026	AARD Aardvark Therapeutics	-$0.87	-$0.66	+$0.21	-$0.66	N/A	N/A
8/6/2026	Q2 2026	RLMD Relmada Therapeutics	-$0.1995	-$0.11	+$0.0895	-$0.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FENC Adherex Technologies	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	12.63	12.63
AVIR Atea Pharmaceuticals	N/A	8.13	8.13
FENC Adherex Technologies	N/A	5.85	5.66
RLMD Relmada Therapeutics	N/A	29.52	29.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
AVIR Atea Pharmaceuticals	86.67%
FENC Adherex Technologies	55.51%
RLMD Relmada Therapeutics	45.24%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	17.80%
AVIR Atea Pharmaceuticals	21.60%
FENC Adherex Technologies	10.73%
RLMD Relmada Therapeutics	14.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.88 million	17.99 million	N/A
AVIR Atea Pharmaceuticals	70	80.21 million	62.88 million	Optionable
FENC Adherex Technologies	10	35.06 million	31.30 million	Optionable
RLMD Relmada Therapeutics	10	106.67 million	91.20 million	Optionable

AARD, RLMD, AVIR, and FENC Headlines

Recent News About These Companies

Seven Fleet Capital Management LP Takes $2.41 Million Position in Relmada Therapeutics, Inc. $RLMD

September 5 at 4:40 AM | marketbeat.com

Relmada’s NDV-01 Bladder Cancer Trial Moves Into Phase 3: What Investors Should Watch

September 2 at 12:50 PM | tipranks.com

Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

September 1, 2026 | globenewswire.com

Corient Private Wealth LP Makes New Investment in Relmada Therapeutics, Inc. $RLMD

September 1, 2026 | marketbeat.com

BlackRock Inc. Makes New Investment in Relmada Therapeutics, Inc. $RLMD

September 1, 2026 | marketbeat.com

After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)

August 31, 2026 | zacks.com

After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)

August 31, 2026 | uk.finance.yahoo.com

Jupiter Topco LLC Invests $77.32 Million in Relmada Therapeutics, Inc. $RLMD

August 28, 2026 | marketbeat.com

Deutsche Bank AG Buys New Position in Relmada Therapeutics, Inc. $RLMD

August 28, 2026 | marketbeat.com

ADAR1 Capital Management LLC Takes Position in Relmada Therapeutics, Inc. $RLMD

August 26, 2026 | marketbeat.com

Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now

August 25, 2026 | zacks.com

6,391,328 Shares in Relmada Therapeutics, Inc. $RLMD Purchased by Spruce Street Capital LP

August 25, 2026 | marketbeat.com

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Receives Consensus Rating of "Moderate Buy" from Analysts

August 17, 2026 | marketbeat.com

616,238 Shares in Relmada Therapeutics, Inc. $RLMD Acquired by Walleye Capital LLC

August 15, 2026 | marketbeat.com

Relmada (RLMD) Q2 2026 Earnings Call Transcript

August 14, 2026 | finance.yahoo.com

Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround

August 11, 2026 | zacks.com

Equities Analysts Issue Forecasts for RLMD Q3 Earnings

August 11, 2026 | marketbeat.com

Relmada Therapeutics (NASDAQ:RLMD) Posts Quarterly Earnings Results, Beats Expectations By $0.09 EPS

August 8, 2026 | marketbeat.com

Relmada Therapeutics (NASDAQ:RLMD) Stock Price Down 6.8% - Time to Sell?

August 7, 2026 | marketbeat.com

Relmada Therapeutics Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD, RLMD, AVIR, and FENC Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$5.38 -0.35 (-6.11%)

As of 09/4/2026 04:00 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Atea Pharmaceuticals NASDAQ:AVIR

$5.83 +0.01 (+0.17%)

As of 09/4/2026 04:00 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Adherex Technologies NASDAQ:FENC

$12.39 -0.16 (-1.27%)

As of 09/4/2026 04:00 PM Eastern

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Relmada Therapeutics NASDAQ:RLMD

$4.43 +0.06 (+1.37%)

As of 09/4/2026 04:00 PM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AARD, RLMD, AVIR, and FENC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AARD, RLMD, AVIR, and FENC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AARD, RLMD, AVIR, and FENC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD, RLMD, AVIR, and FENC Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

Atea Pharmaceuticals NASDAQ:AVIR

Adherex Technologies NASDAQ:FENC

Relmada Therapeutics NASDAQ:RLMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AARD, RLMD, AVIR, and FENC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AARD, RLMD, AVIR, and FENC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AARD, RLMD, AVIR, and FENC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD, RLMD, AVIR, and FENC Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

Atea Pharmaceuticals NASDAQ:AVIR

Adherex Technologies NASDAQ:FENC

Relmada Therapeutics NASDAQ:RLMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools